MCO
GBT

MAK Capital One’s Global Blood Therapeutics, Inc. GBT Stock Holding History

MAK Capital One’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-96,040
Closed -$3.94M – 7
2018
Q4 		$3.94M Buy
+96,040
New +$3.6M 2.14% 6

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

MAK Capital One's GBT Position: Q1 2019 in Review

MAK Capital One sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2019, closing a stake of 96,040 shares — an estimated $3.94M sold.

MAK Capital One first reported a position in GBT in Q4 2018 and held it in 1 quarter. The position peaked at $3.94M in Q4 2018. 201 funds tracked by Wall St. Rank hold GBT as of Q1 2019.

  • MAK Capital One reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • MAK Capital One sold 96,040 Global Blood Therapeutics, Inc. shares in Q1 2019, an estimated $3.94M.
  • MAK Capital One first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • MAK Capital One's Global Blood Therapeutics, Inc. position peaked at $3.94M in Q4 2018.
  • 201 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2019.

Based on MAK Capital One's 13F filing for Q1 2019, filed 15 May 2019.